Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study

American Heart Journal

Volumn 157, Issue 3, 2009, Pages 442-449

  Johnson, Julie A ^a,b   Boerwinkle, Eric ^c   Zineh, Issam ^a,b   Chapman, Arlene B ^d   Bailey, Kent ^e   Cooper DeHoff, Rhonda M ^a,b   Gums, John ^a,b   Curry, R Whit ^b   Gong, Yan ^a   Beitelshees, Amber L ^a   Schwartz, Gary ^e   Turner, Stephen T ^e  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PHARMACOGENOMICS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE MONITORING, AMBULATORY; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; MIDDLE AGED; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; YOUNG ADULT;

EID: 60649094697     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.11.018     Document Type: Article

References (19)

1. AHA. Heart disease and stroke statistics-2008 update (2008), American Heart Assocation, Dallas (Tex)
2. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 289 (2003) 2560-2571
3. Cutler J.A., and Davis B.R. Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation 117 (2008) 2691-2704 [discussion 2705]
4. Messerli F.H., Bangalore S., and Julius S. Risk/Benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 117 (2008) 2706-2715 [discussion 2715]
5. Ma J., and Stafford R.S. Screening, treatment, and control of hypertension in US private physician offices, 2003-2004. Hypertension 51 (2008) 1275-1281
6. Materson B.J. Variability in response to antihypertensive drug treatment. Hypertension 43 (2004) 1166-1167
7. Clement D.L., De Buyzere M.L., De Bacquer D.A., et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 348 (2003) 2407-2415
8. Ohkubo T., Imai Y., Tsuji I., et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 16 (1998) 971-975
9. Stergiou G.S., Baibas N.M., Gantzarou A.P., et al. Reproducibility of home, ambulatory, and clinic blood pressure: implications for the design of trials for the assessment of antihypertensive drug efficacy. Am J Hypertens 15 2 Pt 1 (2002) 101-104
10. Beitelshees A.L., Zineh I., Yarandi H.N., et al. Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension. Pharmacotherapy 26 (2006) 1247-1254
11. Finkielman J.D., Schwartz G.L., Chapman A.B., et al. Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens 18 (2005) 398-402
12. Stergiou G.S., Efstathiou S.P., Skeva, et al. Assessment of drug effects on blood pressure and pulse pressure using clinic, home and ambulatory measurements. J Hum Hypertens 16 (2002) 729-735
13. Mancia G., Omboni S., Parati G., et al. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 8 (1995) 311-315
14. Imai Y., Ohkubo T., Hozawa A., et al. Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebo-controlled open trial. J Hypertens 19 (2001) 179-185
15. Garcia-Estevez D.A., Araujo-Vilar D., Fiestras-Janeiro G., et al. Comparison of several insulin sensitivity indices derived from basal plasma insulin and glucose levels with minimal model indices. Horm Metab Res 35 (2003) 13-17
16. Schroeder K., Fahey T., and Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 164 (2004) 722-732
17. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
18. O'Brien E., Waeber B., Parati G., et al. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 322 (2001) 531-536
19. Keating B.J., Tischfield S., Murray S.S., et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS ONE 3 (2008) e3583